ADC Therapeutics

September 13, 2019

Partnership Aims to Identify DLBCL Patients Likely to Benefit from ADCT-402

News

ADC Therapeutics announced it partnered with Freenome to identify biomarkers that can help to predict which diffuse large B-cell lymphoma (DLBCL) patients are most likely to respond to ADCT-402 (loncastuximab tesirine), ... Read more

February 28, 2019

First Patient Dosed in Trial of ADCT-402/Imbruvica Combo for Advanced DLBCL, MCL

News

A Phase 1 trial testing the combination of ADCT-402 (loncastuximab tesirine) with Imbruvica (ibrutinib) for advanced diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL) has dosed the first patient. Patient ... Read more

February 21, 2019

First Patient Dosed in Trial of ADCT-402 for Advanced Non-Hodgkin’s Lymphoma

News

A Phase 1 trial testing the combination of ADCT-402 (loncastuximab tesirine) with Imfinzi (durvalumab) in multiple types of advanced non-Hodgkin’s lymphoma has dosed the first patient. The study (NCT03685344) is for adults with ... Read more

August 14, 2018

First Patient Dosed in Phase 2 Trial of ADCT-402 in DLBCL

News

ADC Therapeutics has dosed the first participant in its Phase 2 trial assessing ADCT-402 (loncastuximab tesirine) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The trial is expected to support the ... Read more

October 26, 2017

ADC Therapeutics Raises $200M to Fund Two Lead Programs in Non-Hodgkin’s Lymphoma

News

ADC Therapeutics, a company specializing in the development of antibody drug conjugates (ADCs) for several cancer indications, has raised $200 million through a private placement. The financing will be used ... Read more

June 26, 2017June 26, 2017

ADC Reports Positive Phase 1 Results on Antibody-drug Conjugate ADCT-301 for Hodgkin’s, NHL

News

Preliminary results from a Phase 1 trial testing ADC Therapeutics’ ADCT-301 to treat relapsed or refractory Hodgkin’s and non-Hodgkin’s lymphoma (NHL) demonstrated the medication’s therapeutic potential with good overall response rates and low ... Read more